Chinese expert consensus on the clinical application of drug-coated balloon(2nd Edition)OA北大核心

Percutaneous coronary interventions have progressed through the era of plain balloon dilation,bare-metal stent insertion to drug-eluting stent treatment,which has significantly reduced the acute occlusion and restenosis rates of target vess-els and improved patient prognosis,making drug-eluting stents the mainstream interventional treatment for coronary artery dise-ase.In recent years,drug-coated balloons(DCBs)have become a new treatment strategy for coronary artery disease,and the drugs used in the coating and the coating technology have progressed in the past years.Without permanent implant,a DCB delivers ant-iproliferative drugs rapidly and uniformly into the vessel wall via the excipient during a single balloon dilation.Many evidence sug-gests that DCB angioplasty is an effective measure for dealing with in-stent restenosis and de novo lesions in small coronary vessels.As more clinical studies are published,new evidence is emerging for the use of DCB angioplasty in a wide range of coronary diseas-es,and the indications are expanding internationally.Based on the latest research from China and elsewhere,the Expert Writing Com-mittee of the Chinese Expert Consensus on Clinical Applications of Drug-Coated Balloon has updated the previous DCB consensus after evidence-based discussions and meetings in terms of adequate preparation of in-stent restenosis lesions,expansion of the indic-ations for coronary de novo lesions,and precise guidance of DCB treatment by intravascular imaging and functional evaluation.